IJPR  articles are Indexed in SCOPUS (2010 - 2021)Click Here     *Five Years Citation in Google scholar (2016 - 2020) is. 1451*        Now IJPR is Q2 in SJR Ranking     Scopus Coverage of IJPR (2010-2021 Issue 1)          Journal is Currently Not Indexed in Scopus as on february 2021 list provided by scopus

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Study the Causes of the Spread of a Disease Polycythemia Rubra Vera, (PRV) In the Youth Stage, It is Reflected in Heart Diseases, Blood Pressure and Increased Hemoglobin

Author: DR.SALAH KADER
Abstract: Applied academic work, We randomly collected the largest number of patients, men and women of different ages, 730 patients at an age greater than 25 years to treat and search for the real causes and to reduce the factors of the prevalence of polycythemia in Iraq / Samawah city, patients and reviewers, especially at young age, we collected from the files, history, patients and reviewers Outpatient clinics Al Samawa Teaching Hospital, and the private clinic, we relied on clinical diagnosis, laboratory, and x-rays, taking a sample of the bone marrow, the patient’s complaint and suffering, the patient’s external form, assessment of his condition, and the slow disease march for many years with (PV), and we have made arrangement for patients: 1) The first end point Age (25-40) Young people whom we treat primarily receive treatment and all treatment requirements for the stage according to the schedule of reviews and the special file for each patient and are committed to complete treatment for them, while the percentage is 85% in safety, while the2) second end point which includes over 40 Year of polycythemia (PV) who suffer from cardiovascular risk factors patients who are ready for heart diseases, blood vessels, stroke, coronary syndrome and Ischemic attacks, or pulmonary embolism, thrombosis of the veins and arteries, and increased blood viscosity due to the disease More redness and advanced age require more curative care) in addition to polycythemia disease requires intensive care and the provision of all treatments. For heart diseases, chronic diseases and strokes that occur in different parts of the body, and the maintenance of patients was a maximum of 40% in safety. As for the 3) third end point that we cannot predict, the disease develops outside the scope of medical work and after a period of more than 15 years, cancer (leukemia, myeloprolifrative disorder, mellodysplasia, cirrhosis leaver, splenomegaly), The patient must be admitted to the hospitalization immediately and given chemotherapy and intensive follow-up because the side effects threaten the patient’s life with death. The safety rate is 15%. We have divided us in terms of scientific and practical results and daily observations into groups? I th Group: Young ages (25 - 40 years) "Randomized, Primary (PV), high HGB,HCT, WBC, platelet = 480 patient (72.3%), phlebotomy = (76.1%), (2.9 %) low HCT, Hazard ratio HCT = (12%), Incident of death = (0,1 %), Rat death = (0, 0001%), percentage thrombosis arterial and vines risk = (2.4%) According to the blood viscosity and (factor obesity), CI (confidence interval arterial and vines = 1.8 %). RDW = high > 0.1 FI (Increased forms of red blood cells from the bone marrow), JKt2 = + (92%), EPO = Low? II Group: Ages (over 40 years old) are randomized (PV) 350 patient "Randomized. The major causes of morbidity and mortality, Are various heart diseases, chronic diseases that the patient suffers from, risk factors and age JKt 2 = + (65%), High HGB, HCT, WBC, platelet = (70%), phlebotomy = (35%), thrombosis artery or vanes = (9.7%), EPO = Low), Rat death = (4.2%), (2.6) female HCT Low, hazard rate HGB, HCT, WBC, platelet = (9.3 %), Incident of death = (9.8 %), heart disease = (65%). chronic disease = (75%)? III Group: Develop disease 4% patient (Myeloproliferative disorder, leukemia, Carcinoma, Other tumors’), Chemotherapy should be taken as quickly as possible even with treatment, and here plays the role of genetics, genetic mutations JAK2 V617F -, sex, conditions around humans, the nature of food, radiation, and environmental pollution that causes disease and live in high altitude. Our goal is to protect patients from vascular thrombosis among the main causes For death for patients with polycythemia vera (PV). All studies and research are promising to affect the gene that causes the genetic mutations of the disease and its suppression, These findings suggest a direct link between myeloproliferation and thrombogenesis in PV, which is likely to provide new opportunities for targeted antithrombotic interventions aimed at decreasing PV-related morbidity and mortality. Objective / Purpose Searching for the true clinical causes of polycythemia in various ages, especially young people.. Reducing the actual contribution and removing the risk of death from them and raising the harm to people from side effects.. Delaying and searching for the genetic mutation in the development of polycythemia vera.
Keyword: Patients, Pathological Analyzes, Therapeutic Drugs, Risk Factors, Clinical Diagnosis, Modern Radiological Devices, Electrocardiogram, Cardiac Catheters, Chemotherapy.
DOI: https://doi.org/10.31838/ijpr/2020.12.04.270
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free